New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
04:55 EDTEBIO, EBIO, EBIO, EBIO, SURG, SURG, SURG, SURG, DNA, DNA, DNA, DNA, XOMA, XOMA, XOMA, XOMA, SQNM, SQNM, SQNM, SQNM, REGN, REGN, REGN, REGN, MRK, MRK, MRK, MRK, CAJ, CAJ, CAJ, CAJ, AGN, AGN, AGN, AGN, AGTC, AGTC, AGTC, AGTC, VRX, VRX, VRX, VRXAssociation for Research in Vision & Ophthalmology holds annual meeting
2014 Annual Meeting of ARVO is being held in Orlando, Florida on May 4-8.
News For EBIO;AGTC;AGN;CAJ;MRK;REGN;SQNM;XOMA;DNA;SURG;VRX From The Last 14 Days
Check below for free stories on EBIO;AGTC;AGN;CAJ;MRK;REGN;SQNM;XOMA;DNA;SURG;VRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 17, 2014
10:20 EDTAGNPershing sees coming 13-Fs to show long-term Allergan holders have been selling
Subscribe for More Information
09:00 EDTAGNAckman says large takeover by Allergan could be 'enormously value destructive'
08:44 EDTAGNPershing says special meeting warranted given 'poor governance' at Allergan
Subscribe for More Information
08:08 EDTVRXValeant receives FDA clearance for Victus Femtosecond Laser Platform
Subscribe for More Information
07:00 EDTVRX, AGNPaulson says Allergan could be wroth $220 per share, WSJ reports
Subscribe for More Information
July 16, 2014
17:46 EDTAGN, VRXAckman says he thinks Allergan-Valeant deal eventually gets done
Subscribe for More Information
17:42 EDTVRX, AGNPershing Square's Ackman says Allergan's attack on Valeant unprecedented
Subscribe for More Information
10:36 EDTVRX, AGNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:31 EDTAGNPershing Square Capital Management holds analyst/industry conference call
Subscribe for More Information
09:27 EDTEBIOEleven Biotherapeutics management to meet with Leerink
Subscribe for More Information
09:16 EDTAGN, VRXPershing Square sends letter to Allergan's board of directors
Pershing Square Capital Management announced it has sent a letter to Allergan's Board of Directors. Pershing Square last Friday filed definitive solicitation materials with the U.S. SEC to seek shareholder support for a special meeting of Allergan shareholders and is now actively soliciting shareholder support to call the meeting. At this special meeting, Allergan shareholders will be able to voice their opinions on a number of critical matters, including the proposed removal of six incumbent members of the Allergan board, the proposed appointment of an independent slate of directors and certain other proposed provisions to improve Allerganís corporate governance.
08:16 EDTAGN, VRXLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTAGN, VRXTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTMRK, AGNPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
08:11 EDTMRKMerck looks to revive livestock drug Zilmax, WSJ says
Merck has been preparing to conduct a large-scale study this summer to evaluate the safety of its Zilmax feed additive, which the company pulled from the U.S. market last year over concerns in the beef industry that the drug made it difficult for some animals to walk, reported The Wall Street Journal. Reference Link
07:35 EDTMRKPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
July 14, 2014
12:47 EDTVRX, AGNAllergan slides question Valeant growth, disclosures, says BMO Capital
Subscribe for More Information
08:13 EDTAGN, VRXAllergan reiterates belief that Valeant model unsustainable in new presentation
Subscribe for More Information
08:02 EDTVRX, AGNValeant submits HSR filing for proposed acquisition of Allergan
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use